tiprankstipranks
Advertisement
Advertisement
U.K.’s MHRA approves Krystal’s Vyjuvek for dystrophic epidermolysis bullosa
PremiumThe FlyU.K.’s MHRA approves Krystal’s Vyjuvek for dystrophic epidermolysis bullosa
1M ago
Krystal Biotech price target raised to $300 from $295 at Evercore ISI
Premium
The Fly
Krystal Biotech price target raised to $300 from $295 at Evercore ISI
2M ago
Krystal Biotech price target raised to $378 from $371 at Citi
Premium
The Fly
Krystal Biotech price target raised to $378 from $371 at Citi
2M ago
KRYS Earnings this Week: How Will it Perform?
PremiumPre-EarningsKRYS Earnings this Week: How Will it Perform?
2M ago
Krystal Biotech: Valuation Reflects Pipeline Optimism Amid Dosing and Efficacy Risks, Justifying a Hold Rating
Premium
Ratings
Krystal Biotech: Valuation Reflects Pipeline Optimism Amid Dosing and Efficacy Risks, Justifying a Hold Rating
3M ago
Krystal Biotech initiated with a Peer Perform at Wolfe Research
Premium
The Fly
Krystal Biotech initiated with a Peer Perform at Wolfe Research
3M ago
Krystal Biotech: Transitioning to Global Growth as De‑Risked HSV‑1 Gene Therapy Platform Advances Toward Pivotal Stages
PremiumRatingsKrystal Biotech: Transitioning to Global Growth as De‑Risked HSV‑1 Gene Therapy Platform Advances Toward Pivotal Stages
4M ago
Krystal Biotech: Strong Vyjuvek Performance, De‑Risked Gene Therapy Pipeline, and International Expansion Underscore Buy Rating and $318 Target
Premium
Ratings
Krystal Biotech: Strong Vyjuvek Performance, De‑Risked Gene Therapy Pipeline, and International Expansion Underscore Buy Rating and $318 Target
4M ago
Krystal Biotech price target raised to $371 from $336 at Citi
Premium
The Fly
Krystal Biotech price target raised to $371 from $336 at Citi
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100